LU92939I2 - Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable - Google Patents

Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable Download PDF

Info

Publication number
LU92939I2
LU92939I2 LU92939C LU92939C LU92939I2 LU 92939 I2 LU92939 I2 LU 92939I2 LU 92939 C LU92939 C LU 92939C LU 92939 C LU92939 C LU 92939C LU 92939 I2 LU92939 I2 LU 92939I2
Authority
LU
Luxembourg
Prior art keywords
isavuconazonium
salt
isavuconbazole
sulphate
hydrate
Prior art date
Application number
LU92939C
Other languages
English (en)
Original Assignee
Basilea Pharmaceutica Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Int Ltd filed Critical Basilea Pharmaceutica Int Ltd
Publication of LU92939I2 publication Critical patent/LU92939I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
LU92939C 1999-11-02 2016-01-06 Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable LU92939I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99121694 1999-11-02
EP00992946A EP1280795B1 (fr) 1999-11-02 2000-10-25 Derives carbamoyloxyalkyl-azolium n-substitues
PCT/EP2000/010524 WO2001032652A2 (fr) 1999-11-02 2000-10-25 Dérivés carbamoyloxyalkyl-azolium n-substitués

Publications (1)

Publication Number Publication Date
LU92939I2 true LU92939I2 (fr) 2016-03-07

Family

ID=8239312

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92939C LU92939I2 (fr) 1999-11-02 2016-01-06 Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable

Country Status (22)

Country Link
EP (1) EP1280795B1 (fr)
JP (1) JP3787307B2 (fr)
KR (1) KR100449797B1 (fr)
CN (1) CN1185230C (fr)
AR (1) AR029403A1 (fr)
AT (1) ATE291575T1 (fr)
AU (1) AU777859B2 (fr)
BE (1) BE2016C007I2 (fr)
BR (1) BRPI0015254C1 (fr)
CA (2) CA2388320C (fr)
CY (1) CY2016002I1 (fr)
DE (1) DE60018989T2 (fr)
DK (1) DK1280795T3 (fr)
ES (1) ES2238341T3 (fr)
FR (1) FR15C0096I2 (fr)
LU (1) LU92939I2 (fr)
MX (1) MXPA02004145A (fr)
NL (1) NL300791I2 (fr)
PT (1) PT1280795E (fr)
TR (1) TR200201205T2 (fr)
WO (1) WO2001032652A2 (fr)
ZA (1) ZA200203003B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
PT2192893E (pt) 2007-08-21 2015-11-09 Basilea Pharmaceutica Ag Composição antifúngica
AU2012272804B2 (en) 2011-06-22 2017-07-06 Vyome Therapeutics Limited Conjugate-based antifungal and antibacterial prodrugs
MX2015016675A (es) 2013-06-04 2016-07-15 Vyome Biosciences Pvt Ltd Particulas recubiertas y composiciones que comprenden las mismas.
CN104230894B (zh) * 2013-06-06 2016-08-24 南京华威医药科技开发有限公司 三唑类化合物
AU2015380298B2 (en) * 2014-12-30 2019-02-21 Corteva Agriscience Llc Picolinamide compounds with fungicidal activity
CN106032356B (zh) * 2015-03-13 2018-09-14 江苏正大丰海制药有限公司 一种[n-甲基-吡啶-2-基]氨基甲酸-1-氯乙酯的制备方法
CN104974143A (zh) * 2015-05-12 2015-10-14 深圳致君制药有限公司 一种季铵盐类化合物、其制备方法以及用途
CN106467519B (zh) * 2015-08-17 2019-08-13 南京华威医药科技集团有限公司 一种水溶性三唑化合物
CN106467534B (zh) * 2015-08-17 2019-10-11 江苏奥赛康药业有限公司 一种硫酸艾沙康唑鎓化合物及其药物组合物
CN106565699B (zh) * 2015-10-10 2019-07-26 江苏正大丰海制药有限公司 一种艾沙康唑硫酸盐晶体及其制备方法
WO2018067702A1 (fr) 2016-10-04 2018-04-12 Massachusetts Institute Of Technology Copolymères en forme de goupillon et leurs utilisations
CN108456194B (zh) * 2017-02-17 2021-06-22 武汉朗来科技发展有限公司 三氮唑抗菌衍生物、其药物组合物和用途
CN106916152B (zh) * 2017-04-27 2019-09-17 扬子江药业集团有限公司 氧化还原反应制备艾沙康唑鎓单硫酸盐的方法
JP7187048B2 (ja) 2017-06-30 2022-12-12 マサチューセッツ インスティテュート オブ テクノロジー 分枝多官能性マクロモノマーおよび関連ポリマーならびにそれらの使用
US11752221B2 (en) 2017-06-30 2023-09-12 Massachusetts Institute Of Technology Brush-arm star polymer imaging agents and uses thereof
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
CN110317165A (zh) * 2018-03-28 2019-10-11 上海医药工业研究院 一种药物中间体2-甲胺基-3-吡啶甲醇的制备方法
CN110551064B (zh) * 2018-06-01 2021-01-01 重庆世森医药科技有限公司 艾沙康唑硫酸酯及其中间体的制备方法
KR20210040034A (ko) 2018-08-01 2021-04-12 바실리어 파마슈티카 인터내셔널 리미티드 이사부코나조늄 설페이트의 정제 방법
US10988491B2 (en) 2018-08-17 2021-04-27 Massachusetts Institute Of Technology Degradable polymers of a cyclic silyl ether and uses thereof
CN110128420A (zh) * 2019-05-08 2019-08-16 阴启明 硫酸氢根/硫酸根型阴离子交换技术制备艾沙康唑鎓单硫酸盐的方法
US20220289735A1 (en) 2019-08-26 2022-09-15 Synthon B.V. Isavuconazonium salts and process for preparing thereof
CA3154334A1 (fr) * 2019-10-16 2021-04-22 Jeremiah A. Johnson Promedicaments a brosse et leurs utilisations
WO2021141662A1 (fr) 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Molécules chimériques ciblant la protéolyse (protacs) à bras fonctionnels et leurs utilisations
JP7454905B2 (ja) * 2021-09-28 2024-03-25 旭化成ファーマ株式会社 有効成分であるイサブコナゾール又はそのプロドラッグを含有する真菌症治療及び／又は予防剤
WO2023054310A1 (fr) 2021-09-28 2023-04-06 Basilea Pharmaceutica International Ag, Allschwil Ensemble de perfusion goutte-à-goutte intraveineux pourvu d'un filtre de perfusion à évent d'air
WO2023121753A1 (fr) 2021-12-20 2023-06-29 Massachusetts Institute Of Technology Conjugués biomolécule-polymère-agent pharmaceutique pour administrer l'agent pharmaceutique
EP4289840A1 (fr) 2022-06-07 2023-12-13 Zaklady Farmaceutyczne Polpharma S.A. Procede de preparation de sulfate d'isavuconazonium
WO2024094329A1 (fr) 2022-11-01 2024-05-10 Basilea Pharmaceutica International Ag, Allschwil Préparation de capsule sous emballage coque contenant du sulfate d'isavuconazonium
WO2024189550A1 (fr) * 2023-03-13 2024-09-19 Apitoria Pharma Private Limited Procédé de préparation de sulfate d'isavuconazonium et ses formes cristallines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3108997B2 (ja) * 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
ATE244715T1 (de) * 1997-03-31 2003-07-15 Takeda Chemical Industries Ltd Azol-verbindungen, ihre herstellung und ihre verwendung
AU2931399A (en) * 1998-03-06 1999-09-20 F. Hoffmann-La Roche Ag 3-(4-(4-cyanophenyl)thiazol-2-y))-1-(1h-1,2,4-triazol-1-yl) -butan-2-ol derivatives having antifungal activity

Also Published As

Publication number Publication date
ATE291575T1 (de) 2005-04-15
CA2680292C (fr) 2012-11-27
EP1280795B1 (fr) 2005-03-23
BE2016C007I2 (fr) 2019-10-23
CY2016002I2 (el) 2016-10-05
WO2001032652A3 (fr) 2001-11-15
KR100449797B1 (ko) 2004-09-30
AU2835201A (en) 2001-05-14
CA2388320C (fr) 2009-12-15
DE60018989D1 (de) 2005-04-28
CN1185230C (zh) 2005-01-19
ZA200203003B (en) 2003-09-23
PT1280795E (pt) 2005-06-30
BR0015254B1 (pt) 2013-05-21
ES2238341T9 (es) 2016-03-02
JP2003513090A (ja) 2003-04-08
FR15C0096I2 (fr) 2016-04-22
KR20020062298A (ko) 2002-07-25
MXPA02004145A (es) 2002-10-17
FR15C0096I1 (fr) 2016-02-12
BRPI0015254C1 (pt) 2021-05-25
BR0015254A (pt) 2002-06-25
AR029403A1 (es) 2003-06-25
JP3787307B2 (ja) 2006-06-21
WO2001032652A2 (fr) 2001-05-10
BRPI0015254B8 (pt) 2017-04-25
NL300791I1 (fr) 2016-03-15
DE60018989T2 (de) 2005-08-18
EP1280795A2 (fr) 2003-02-05
CA2388320A1 (fr) 2001-05-10
NL300791I2 (fr) 2016-03-15
CN1387529A (zh) 2002-12-25
ES2238341T3 (es) 2005-09-01
AU777859B2 (en) 2004-11-04
DK1280795T3 (da) 2005-07-18
CY2016002I1 (el) 2016-10-05
CA2680292A1 (fr) 2001-05-10
TR200201205T2 (tr) 2002-08-21

Similar Documents

Publication Publication Date Title
LU92939I2 (fr) Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable
LU91681I2 (fr) "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)"
LU91442I2 (fr) "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU92428I2 (fr) Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
LU92397I2 (fr) Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
MA26641A1 (fr) Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments
IS4394A (is) Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra
IL164555A0 (en) 4-'7-Halo-2-quino (xa-)linyloxy! phenoxy-propionicacid derivatives as antineoplastic agents
FR2862279B1 (fr) Ballon gonflable a facettes pour l'evenementiel
TH52440EX (th) " ไฟฉาย "
TH59434EX (th) ขวด
DE60023072D1 (de) Wässrige Dispersionen
TH47542EX (th) ถัง
GB9910151D0 (en) Multivalent agents for use in the treatmnet of mitochondrial diseases
ZA200205112B (en) Pharmaceutical composition comprising pemetrexed together with monothioglycerol L-cystein or thioglycolic acid.
TH50938EX (th) เครื่องผลิตน้ำประปาสำเร็จรูป
ZA200001464B (en) 142b/124 blowing agent blends.
TH54233EX (th) ปากกา
TH54234EX (th) ปากกา
TH47149EX (th) ปากกา
TH50937EX (th) เครื่องผลิตน้ำประปาบาดาลสำเร็จรูป
TH42361EX (th) ชาม
SE9903774D0 (sv) Hålslag kongerens
TH53860EX (th) กล่องกระดาษชำระ